Related Experiment Videos
Autoantibodies to factor VIII with catalytic activity
Jagadeesh Bayry1, Sébastien Lacroix-Desmazes, Anastas Pashov
1INSERM, U430, Hôpital Broussais, 96, rue Didot, 75014 Paris, France.
Autoimmunity Reviews
|July 10, 2003
Summary
Hemophilia A patients can develop inhibitors that neutralize factor VIII (FVIII). These antibodies act as proteases, breaking down FVIII and causing bleeding complications.
Area of Science:
- Immunology
- Hematology
- Biochemistry
Background:
- Hemophilia A is a genetic bleeding disorder due to Factor VIII (FVIII) deficiency.
- Inhibitors (anti-FVIII antibodies) develop in ~25% of severe hemophilia A patients treated with FVIII infusions.
- Current understanding suggests inhibitors neutralize FVIII via steric hindrance.
Purpose of the Study:
- To investigate a novel mechanism of FVIII inhibitor function.
- To explore the role of proteolysis in FVIII inhibitor activity.
- To characterize FVIII inhibitors as catalytic antibodies in humans.
Main Methods:
- Analysis of allo-antibody activity in high responder hemophilia A patients.
- Assessment of FVIII proteolysis by patient-derived antibodies.
- Characterization of antibody-mediated FVIII hydrolysis.
Main Results:
- Demonstrated that FVIII inhibitors can proteolyze (hydrolyze) FVIII molecules.
- Established a direct link between FVIII hydrolysis and clinical manifestations in hemophilia.
- Identified FVIII inhibitors as site-specific proteases, a first in human antigen-induced antibody catalysis.
Conclusions:
- FVIII inhibitors function as proteases, degrading FVIII and contributing to clinical symptoms.
- This proteolysis mechanism offers a new understanding of inhibitor activity in hemophilia A.
- Characterizing inhibitors as proteases may lead to novel therapeutic strategies for managing inhibitors.